Immunomic Therapeutics to Participate at World Vaccine Congress Washington 2020

Sept. 14, 2020 12:00 UTC



ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics Inc. (ITI) announced today that it will participate at the World Vaccine Congress Washington being held virtually September 28-October 1, 2020. Andrew Eisen, MD, Ph.D., Immunomic’s Vice President of Clinical Development, will present a talk titled, “Pharmacodynamic Imaging in a CMV Vaccine Trial for Glioblastoma.”

In addition, Immunomic Therapeutics, lead founder and supporter of Why We Vax, a non-profit whose mission is to help educate communities with research backed facts on vaccines, will be leading a Q&A panel titled, “What If They Gave a COVID-19 Vaccine and Nobody Came,” at 3:50pm EST on October 1, 2020.

“Vaccines are one of the safest, most widely-adopted health care practices in the world. Why We Vax will spread the message that vaccines are rigorously tested and provide the best defense against diseases. One example is Measles, which can have a lasting impact on a child’s immune system,” said Dr. William Hearl, Why We Vax Chairman, Immunomic Therapeutics CEO, and experienced vaccinologist.

The World Vaccine Congress Washington is a multi-faceted conference experience with over 300 industry leading speakers, exclusive interviews, world leading presentations, live panel debates, and virtual face to face meetings.

Presentation details are as follows:

Dr. Andrew Eisen Presentation
Pharmacodynamic Imaging In A CMV Vaccine Trial For GBM
Panel Category: Cancer and Immunotherapy Track
Panel Date and Time: Wednesday, September 30, 2020 2:30PM

Why We Vax Q&A Panel
What If They Gave a COVID-19 Vaccine and Nobody Came
Category: Vaccine Safety track: Risk Assessment & Communication of Safety
Date and Time: Thursday, October 1, 2020 3:50PM


ITI’s investigational UNITE platform, or UNiversal Intracellular Targeted Expression, is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in humans. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.

About ITI-1000 and the Phase 2 (ATTAC-II) Study

ITI-1000 is an investigational dendritic cell vaccine therapy currently in a Phase 2 clinical trial (ATTAC-II) for the treatment of GBM. ITI-1000 was developed using Immunomic’s proprietary investigational lysosomal targeting technology, UNITE, in the context of cell therapy. In May 2017, Immunomic exclusively licensed a patent portfolio from Annias Immunotherapeutics for use in combination with UNITE and ITI-1000, allowing Immunomic to combine UNITE with a patented and proprietary CMV immunotherapy platform. The ATTAC-II study (NCT02465268) is a Phase II randomized, placebo-controlled clinical trial enrolling patients with newly diagnosed GBM that will explore whether dendritic cell (DC) vaccines, including ITI-1000, targeting the CMV antigen pp65 improves survival. This study is enrolling up to 120 subjects at 3 clinical sites in the United States. For more information on the ATTAC-II study, please visit

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary investigational technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body’s natural biochemistry to develop vaccines that generate broad immune responses. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including viral antigens, cancer antigens, neoantigens and antigen-derived antibodies as biologics. The Company has built a large pipeline from UNITE with six oncology programs and two allergy programs. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit


Company Contact:
Sia Anagnostou

Media Contact:
Amy Conrad
Juniper Point


Source: Immunomic Therapeutics, Inc.

Back to news